Is Orforglipron (Foundayo) Safe During Pregnancy?

Orforglipron (Foundayo) is not recommended during pregnancy. Per its FDA-approved label on DailyMed, there are no adequate studies of the drug in pregnant women, animal data suggest a risk of fetal harm, and the label directs that it be discontinued once pregnancy is recognized. This is a class-wide pattern for GLP-1 weight-management medications, not something unique to orforglipron — here’s what the label actually says, and where the real gaps in the data are.

What the FOUNDAYO label says about pregnancy

Per DailyMed’s FOUNDAYO prescribing information, there are no adequate and well-controlled studies of orforglipron in pregnant women. Based on animal reproduction studies, the label notes there may be risks to a developing fetus from exposure to orforglipron during pregnancy, and states that orforglipron may cause fetal harm. Because of that, the label’s guidance is straightforward: when pregnancy is recognized, discontinue FOUNDAYO.

This isn’t framed as “stop taking it eventually” — it’s a discontinue-on-recognition instruction, which is why timing matters if you’re planning a pregnancy while on orforglipron. That timing decision belongs with your prescriber, since the label doesn’t publish a general-purpose pre-conception washout window for the public to apply on their own.

Why weight-management GLP-1s carry this warning

A recurring theme in weight-management drug labels — not just orforglipron’s — is that intentional weight loss during pregnancy is not considered beneficial and may itself pose risk, separate from any direct effect of the drug. Combined with limited human pregnancy data for a relatively new drug class, that’s a large part of why orforglipron, and GLP-1 receptor agonists generally, carry cautious pregnancy language.

Semaglutide (the active ingredient in Ozempic, Wegovy, and Rybelsus) follows the same pattern. Per MedlinePlus drug information, semaglutide’s pregnancy guidance similarly points to potential fetal risk based on animal reproduction data and advises discontinuation once pregnancy is recognized, since weight loss offers no benefit to a pregnant patient and may cause fetal harm. Tirzepatide (Mounjaro, Zepbound) is in the same broader incretin-based drug category and carries comparable cautions per its own MedlinePlus entry.

How orforglipron compares to other GLP-1s on this point

The pregnancy and lactation cautions aren’t unique to any one brand — here’s how orforglipron’s labeling lines up against the other GLP-1 and dual-agonist medications people commonly compare it to:

	Orforglipron (Foundayo)	Semaglutide (Ozempic/Wegovy)	Semaglutide (Rybelsus)	Tirzepatide (Mounjaro/Zepbound)
Drug class	GLP-1 receptor agonist (small molecule)	GLP-1 receptor agonist (peptide)	GLP-1 receptor agonist (peptide)	Dual GIP/GLP-1 receptor agonist (peptide)
Human pregnancy data	Not adequate/well-controlled per label	Insufficient to establish drug-associated risk per label	Insufficient to establish drug-associated risk per label	Limited, per MedlinePlus
Guidance if pregnancy occurs	Discontinue when pregnancy is recognized	Discontinue when pregnancy is recognized	Discontinue when pregnancy is recognized	Discuss with prescriber promptly
Pregnancy exposure registry	Yes, per FDA label (contact Eli Lilly)	Yes, per FDA label	Manufacturer-specific	Manufacturer-specific

Sources: FOUNDAYO FDA label (DailyMed) and the MedlinePlus semaglutide and tirzepatide pages, linked below. This table reflects labeling patterns for the class, not a claim that all four drugs carry identical, word-for-word pregnancy language — check each drug’s own current label for specifics.

What about breastfeeding?

Per the FOUNDAYO label, orforglipron is not recommended for nursing women. In animal studies, orforglipron was detected in breast milk. The label’s guidance is to weigh the developmental and health benefits of breastfeeding against the mother’s clinical need for the medication and any potential effects on the breastfed child — a decision the label frames as one to make with a healthcare provider, not a blanket “never” or “always safe.”

If you’re trying to conceive while on orforglipron

A few things worth knowing before that conversation with your prescriber:

• This medication is not something to stop or continue on your own based on a general article — pregnancy planning involves your full health picture, not just one drug’s label.
• The label directs discontinuation once pregnancy is recognized, not necessarily before you start trying — but many prescribers plan medication changes ahead of a pregnancy attempt rather than after the fact. Ask your prescriber what timeline makes sense for you.
• A pregnancy exposure registry exists. Per the FDA label, if you or a patient becomes pregnant while taking FOUNDAYO, you’re encouraged to contact Eli Lilly directly so the outcome can be tracked — this is how the drug’s real-world pregnancy safety data accumulates over time, since pre-approval trials typically exclude pregnant participants.
• If a switch to a different GLP-1 or a pause in treatment is part of your plan, Switching to Orforglipron and Orforglipron vs Tirzepatide cover the general differences between options — but the pregnancy-specific timing still has to come from your prescriber.

For contraception-specific questions, see Does Orforglipron Affect Birth Control?

What this article won’t do

It won’t tell you when to stop orforglipron before trying to conceive, whether to continue it if you’re already pregnant, or whether it’s “safe enough” for your specific situation. None of that is answerable from a drug label alone — it depends on your health history, how far along a pregnancy is, and factors only your prescriber can evaluate. This article summarizes what the FDA label and comparable MedlinePlus entries say; it isn’t a substitute for that conversation.

Bottom line

Orforglipron (Foundayo) is not recommended during pregnancy, per its FDA label, which directs discontinuation once pregnancy is recognized based on limited human data and animal studies suggesting potential fetal harm. It’s also not recommended while breastfeeding. Both cautions mirror the broader GLP-1 class — semaglutide and tirzepatide carry similar warnings — rather than being specific to orforglipron. If pregnancy is a possibility for you while on orforglipron, or you’re already pregnant, talk to your prescriber promptly rather than making the call based on this or any general guide. For the fuller picture on orforglipron’s dosing and administration, see Foundayo (Orforglipron): A Simple Guide, and for its broader side-effect profile, Orforglipron Side Effects.